Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study (Q40821688)
Jump to navigation
Jump to search
scientific article published on 22 January 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study |
scientific article published on 22 January 2016 |
Statements
1 reference
Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study (English)
1 reference
Paul Kwo
1 reference
Norman Gitlin
1 reference
Ronald Nahass
1 reference
David Bernstein
1 reference
Kyle Etzkorn
1 reference
Sergio Rojter
1 reference
Eugene Schiff
1 reference
Mitchell Davis
1 reference
Peter Ruane
1 reference
Ziad Younes
1 reference
Ronald Kalmeijer
1 reference
Rekha Sinha
1 reference
Monika Peeters
1 reference
Oliver Lenz
1 reference
Bart Fevery
1 reference
Guy De La Rosa
1 reference
Jane Scott
1 reference
James Witek
1 reference
22 January 2016
1 reference
1 reference
Identifiers
1 reference